Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.

Publication ,  Journal Article
Stover, JT; Moore, RA; Davis, K; Harrison, MR; Armstrong, AJ
Published in: Prostate Cancer Prostatic Dis
June 2015

BACKGROUND: Owing to efficacy and tolerability, abiraterone acetate (AA) is a leading treatment for men with metastatic castration-resistant prostate cancer. Increased serum concentrations of AA, such as by taking AA with food, may lead to the inhibition of additional enzymes in the androgen synthesis pathway implicated in castration-resistant prostate cancer progression. METHODS: Medical records of men with metastatic castration-resistant prostate cancer (mCRPC) who received AA between 1 April 2011 and 31 December 2013 were retrospectively reviewed. The primary outcome was the percent of men with a rising PSA on AA who experienced any PSA decline within 3 months after changing the administration of AA from without food to with food. Secondary outcomes were median time on AA therapy in men who received AA therapy without food versus those that switched administration from without food to with food at PSA progression, and the percent of men who experienced any decline in serum testosterone concentration, and the rate of adverse events observed while taking AA with food. RESULTS: Nineteen men who switched AA administration from without food to with food and 41 patients who administered AA without food only were included in the study. Of those patients who took AA with food at PSA progression, a PSA decline was observed in 3 of the 19 (16%) men, including 3 of the 14 men who had an initial response to AA (21%). Testosterone declined in five out of seven patients from pre-food levels. The median time on AA therapy was increased by nearly 100 days in patients who switched AA administration from without food to with food. No increases in toxicity were observed. CONCLUSION: Some men with mCRPC may benefit from taking AA with food. Further prospective comparative studies are needed to determine if changing AA administration is beneficial.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

June 2015

Volume

18

Issue

2

Start / End Page

161 / 166

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Prostatic Neoplasms, Castration-Resistant
  • Prostate-Specific Antigen
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Humans
  • Disease-Free Survival
  • Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stover, J. T., Moore, R. A., Davis, K., Harrison, M. R., & Armstrong, A. J. (2015). Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis, 18(2), 161–166. https://doi.org/10.1038/pcan.2015.7
Stover, J. T., R. A. Moore, K. Davis, M. R. Harrison, and A. J. Armstrong. “Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.Prostate Cancer Prostatic Dis 18, no. 2 (June 2015): 161–66. https://doi.org/10.1038/pcan.2015.7.
Stover JT, Moore RA, Davis K, Harrison MR, Armstrong AJ. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):161–6.
Stover, J. T., et al. “Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer.Prostate Cancer Prostatic Dis, vol. 18, no. 2, June 2015, pp. 161–66. Pubmed, doi:10.1038/pcan.2015.7.
Stover JT, Moore RA, Davis K, Harrison MR, Armstrong AJ. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):161–166.

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

June 2015

Volume

18

Issue

2

Start / End Page

161 / 166

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Treatment Outcome
  • Prostatic Neoplasms, Castration-Resistant
  • Prostate-Specific Antigen
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Humans
  • Disease-Free Survival
  • Aged